Paper Details

  1. Home
  2. Paper Details

Evaluaton of therapy with cabergoline in men with macroprolactinoa.

Author: Andrysiak-MamosElzbieta, Kaźmierczyk-PuchalskaAgnieszka, KojderIreneusz, SaganLeszek, Sowińska-PrzepieraElzbieta, SyreniczAnhelli, ZochowskaEwa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Cabergoline, a selective dopamine receptor agonist, is a treatment option for prolactinoma. This study evaluated the efficacy of cabergoline therapy in men with macroprolactinoma, based on clinical, hormonal, and radiological examinations.
Paper Details　
Original Abstract of the Article :
Pituitary gland adenomas producing prolactin are one of the commonest hormonally active tumours. Pharmacological treatment using of dopamine receptors agonists is the therapy of choice in a case of prolactinoma. Bromocriptine, which causes numerous side-effects is the most commonly used drug. Recent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/27344867

データ提供：米国国立医学図書館（NLM）

Cabergoline for Macroprolactinoma: A Promising Treatment

Prolactinomas, benign tumors of the pituitary gland that produce prolactin, are a common cause of hormonal imbalances. This study investigates the effectiveness of cabergoline, a dopamine receptor agonist, in treating macroprolactinomas in men.

Cabergoline Demonstrates Efficacy in Treating Macroprolactinomas

The study evaluated the therapeutic effects of cabergoline in men with macroprolactinomas. The results showed positive outcomes based on clinical, hormonal, and radiological assessments. Cabergoline, with its prolonged duration of action, demonstrated good results in reducing prolactin levels and tumor size, suggesting its potential as an effective treatment option for macroprolactinomas.

Improving Treatment for Macroprolactinomas

This research offers valuable insights into the management of macroprolactinomas. The study's findings suggest that cabergoline is a promising treatment option, potentially offering improved outcomes compared to bromocriptine, which is associated with more side effects. Further research is needed to confirm its long-term efficacy and safety for treating macroprolactinomas.

Dr. Camel's Conclusion

The study's findings are encouraging for individuals with macroprolactinomas. Just as a camel endures long journeys in the desert, we must seek innovative approaches to effectively manage this hormonal condition. This research highlights the potential of cabergoline as a valuable therapeutic option, offering hope for improved outcomes for patients.

Date :
  1. Date Completed 2016-07-26
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27344867

DOI: Digital Object Identifier

27344867

Related Literature

Article Analysis
・Side Effects of bromocriptine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.